As a multikinase inhibitor, sorafenib blocks a broad spectrum of malignant phenotypes, including cell proliferation, tumor angiogenesis, and metastasis of HCC, by repressing the activity of tyrosine kinase receptors to inhibit PI3K/AKT and the Ras/Raf/MAPK pathway (Carlomagno et al., 2006; Wellbrock et al., 2004; Wilhelm et al., 2004). This evidence concerns the gene AKT1 and hepatocellular carcinoma.